company featured image

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well-tolerated, oral treatments of cancer and other serious illnesses.

 

Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.

 

READ MORE

pipeline featured image

Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, pancreatic cancer, breast cancer, and prevention of acute kidney injury in hospitalized patients with pneumonia.

 

READ MORE

doctor viewing vaccine

May 2024 – Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon’s previous orphan drug designation for the treatment of glioblastoma, received in early 2023.”

 

March 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, delivering a podium presentation titled, ““Delving into a Clinical Update on Azeliragon for GBM – Implementable Lessons for Small Molecule Success.”

 

February 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

 

READ ALL NEWS

CANTEX IS DEVELOPING AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA, BRAIN METASTASES, BREAST CANCER, PANCREATIC CANCER AND PREVENTION OF ACUTE KIDNEY INJURY IN SERIOUSLY ILL PATIENTS.